Research
Hormonal
Glucagon-like peptide-1 receptor agonists have shown potential in treating obesity and reducing the risk of type 2 diabetes.
Healthcare providers may consider glucagon-like peptide-1 receptor agonists as a treatment option for obesity and diabetes risk reduction.
StrongSupportsmedium confidence
Glucagon-like peptide-1 receptor agonists have shown potential in treating obesity and reducing the risk of type 2 diabetes.
Why this rating
The review suggests a comprehensive evaluation of existing studies.
Source
Safety of glucagon-like peptide-1 receptor agonists for weight management in adults, adolescents, and children with obesity: a scoping review
Christoffer Storm Baden et al. · Adverse Drug Reaction Bulletin · 2023
reviewCited 2×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →